AChE

Cat. No.

A78648

CAS No.

2499488-78-5

BuChE-IN-3

BuChE-IN-3 is a selective inhibitor of butyrylcholinesterase (BuChE) with an IC50 of 8.3 nM. This compound demonstrates neuroprotective properties and exhibits mild antioxidant activity, making it suitable for studies related to neurodegenerative diseases. Its favorable lipophilicity and low toxicity profile further support its potential in chemical research applications aimed at exploring BuChE's role in various biological processes.

Cat. No.

A78649

CAS No.

955034-69-2

K203

K203 is a potent reactivator of acetylcholinesterase (AChE) inhibited by tabun. This compound is a vital antidote for organophosphate poisoning, restoring AChE activity and mitigating the toxic effects of nerve agents. Its application is significant in toxicology research and therapeutic interventions for chemical warfare agent exposure.

Cat. No.

A78650

CAS No.

41093-89-4

Echimidine N-oxide

Echimidine N-oxide is a pyrrolizidine alkaloid that serves as an acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.347 mM. This compound is utilized in research applications focusing on neurological disorders and cholinergic system modulation. Its inhibitory activity on ChE provides valuable insights into potential therapeutic strategies for conditions associated with cholinergic dysregulation.

Cat. No.

A78651

CAS No.

693268-77-8

ChEs/MAOs-IN-2

ChEs/MAOs-IN-2 is a potent inhibitor of cholinesterases and monoamine oxidases, exhibiting IC50 values of 0.10 µM for MAO-A, 0.20 µM for MAO-B, 0.30 µM for acetylcholinesterase (AChE), and 0.40 µM for butyrylcholinesterase (BChE). This compound demonstrates significant biological activity relevant to neurodegenerative diseases, particularly Alzheimer's disease, and serves as a valuable tool for research into therapeutic strategies targeting these enzymes.

Cat. No.

A78652

CAS No.

163089-71-2

Huperzine C

Huperzine C is an alkaloid derived from Huperzia serrate, functioning as a potent acetylcholinesterase (AChE) inhibitor with an IC50 value of 0.6 μM. This compound has demonstrated significant biological activity in enhancing acetylcholine levels, making it a valuable tool for research related to Alzheimer’s disease and other neurodegenerative disorders. Its mechanism of action highlights its potential utility in studies aimed at developing therapeutic strategies for cognitive decline.

Cat. No.

A78653

CAS No.

64924-06-7

Scutellarein 4'-methyl ether 7-O-glucuronide

Synonyms: Clerodendroside

Scutellarein 4'-methyl ether 7-O-glucuronide is a flavonoid compound that acts as an inhibitor of acetylcholinesterase (AChE), with an IC50 value of 1 mg/mL. Isolated from Plectranthus barbatus, this compound exhibits antioxidant properties and is significant for research into neurological disorders, particularly Alzheimer's disease. Its dual function as an AChE inhibitor and antioxidant makes it valuable for studies exploring therapeutic strategies in cognitive health.

Cat. No.

A78654

CAS No.

139306-10-8

Rivastigmine metabolite

Synonyms: NAP 226-90

Rivastigmine metabolite (NAP 226-90) is an acetylcholinesterase (AChE) inhibitor that plays a significant role in the modulation of cholinergic neurotransmission. This compound is a key metabolite formed in the kidney and is of particular interest for research into Alzheimer's Disease. Its inhibitory action on AChE highlights its potential for studying therapeutic approaches in neurodegenerative conditions characterized by cholinergic deficits.

Cat. No.

A78655

CAS No.

6164-47-2

Protopine hydrochloride

Synonyms: Corydinine hydrochloride

Protopine hydrochloride is a reversible and competitive inhibitor of acetylcholinesterase. This isoquinoline alkaloid demonstrates significant anti-inflammatory, antimicrobial, anti-angiogenic, and anti-tumor properties. It can be utilized in various research applications, particularly in studies related to neurodegenerative diseases, cancer, and inflammatory disorders.

Cat. No.

A78656

CAS No.

69772-72-1

Stemoninine

Stemoninine is a lycoris alkaloid that acts as an inhibitor of acetylcholinesterase (AChE), exhibiting a significant inhibitory effect with an IC50 value of 5.52 μM. This compound demonstrates potential antitussive properties, making it a valuable reagent for research involving respiratory conditions and cholinergic signaling pathways. Its ability to modulate AChE activity is important for studies focusing on neurodegenerative diseases and synaptic transmission.

Cat. No.

A78657

CAS No.

317-52-2

Hexafluorenium dibromide

Synonyms: Mylaxen

Hexafluorenium dibromide is a potent cholinesterase (ChE) inhibitor, exhibiting a pI50 value of 6.96 and a Ki value of 2.4 nM for human plasma cholinesterase. This compound is primarily utilized in research focused on the modulation of cholinergic activity and is relevant for studies investigating neurodegenerative diseases and muscle disorders. Its strong inhibition of ChE makes it a valuable tool for exploring the dynamics of acetylcholine in biological systems.

Cat. No.

A78658

CAS No.

13415-07-1

Octahydroaminoacridine

Octahydroaminoacridine is a potent inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BChE), serving as a valuable tool in cholinergic research. Its activity can enhance understanding of neurodegenerative conditions, particularly Alzheimer's disease (AD). This compound offers insight into mechanisms of cholinesterase inhibition, supporting the development of therapeutic strategies for cognitive disorders.

Cat. No.

A78660

CAS No.

1013-96-3

(E)-2-Nitrocinnamic acid

(E)-2-Nitrocinnamic acid is an effective acetylcholinesterase inhibitor. Its primary mechanism of action involves the modulation of acetylcholine levels, which is significant for neurochemical research. This compound is particularly relevant for studies related to Alzheimer's disease and other neurodegenerative disorders, providing valuable insights into potential therapeutic approaches.

Cat. No.

A78662

CAS No.

27631-29-4

DCDQ

DCDQ is a potent inhibitor of acetylcholinesterase (AChE), demonstrating strong binding affinity for the 4EY7 protein with a binding energy of −8.2 kcal/mol. This compound is of significant interest in the research of Alzheimer's disease (AD), where AChE inhibition may enhance cholinergic transmission and potentially improve cognitive function. DCDQ serves as a valuable tool for investigating therapeutic strategies aimed at mitigating the effects of neurodegenerative disorders.

Cat. No.

A78663

CAS No.

89020-33-7

Territrem C

Territrem C is a potent acetylcholinesterase (AChE) inhibitor, exhibiting an IC50 value of 0.23 μM. This compound, categorized as an α-pyrone meroterpenoid, is derived from the fungus Penicillium sp. SK5GW1L. Territrem C is primarily utilized in biological research to study cholinergic signaling pathways and to explore potential therapeutic strategies for conditions associated with AChE dysfunction.

Cat. No.

A78664

CAS No.

2421120-96-7

AChE/BChE-IN-8

AChE/BChE-IN-8 is an uncompetitive inhibitor of acetylcholinesterase (AChE) and a mixed inhibitor of butyrylcholinesterase (BChE), demonstrating Ki values of 0.788 μM and 2.364 μM against Electrophorus electricus AChE and equine BChE, respectively. This compound is capable of crossing the blood-brain barrier and exhibits low cytotoxicity, making it suitable for neurological research applications. AChE/BChE-IN-8 can be effectively utilized in studies focused on cholinergic signaling, neurodegenerative diseases, and the modulation of cholinergic activity.

Cat. No.

A78665

CAS No.

40709-76-0

RX 67668

RX 67668 is a potent cholinesterase inhibitor, demonstrating an IC50 of 5 μM for both acetylcholinesterase (AChE) and butyrylcholinesterase. This compound effectively reverses neuromuscular blockade induced by D-tubocurarine. RX 67668 has applications as a muscle relaxant and is utilized in research focused on alleviating skeletal muscle fatigue.

Cat. No.

A78666

CAS No.

16850-91-2

Dehydrogeijerin

Dehydrogeijerin is a potent inhibitor of acetylcholinesterase, exhibiting an IC50 value of 9.7 μM. This compound is particularly relevant for research into Alzheimer’s disease, where the modulation of acetylcholine levels can influence disease pathology. Dehydrogeijerin's ability to inhibit acetylcholinesterase makes it a valuable tool for exploring therapeutic strategies aimed at enhancing cholinergic signaling in neurodegenerative disorders.

Cat. No.

A78667

CAS No.

3078693-67-8

AChE-IN-86

AChE-IN-86 is a potent inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 of 25.33 μg/mL. This compound effectively inhibits AChE by forming hydrogen bonds and π-π and π-alkyl interactions with critical amino acid residues at the enzyme's catalytic sites. AChE-IN-86 is applicable in research focused on Alzheimer's disease, making it a valuable tool for studying cholinergic dysfunction associated with neurodegeneration.

Cat. No.

A78668

CAS No.

1538575-22-2

Paecilomide

Paecilomide is a pyridone alkaloid that acts as an acetylcholinesterase inhibitor. This compound exhibits key biological activity by enhancing cholinergic signaling, making it significant for research applications related to neurodegenerative diseases such as Alzheimer's. Its ability to inhibit acetylcholinesterase enables the study of cholinergic neurotransmission and potential therapeutic interventions.

Cat. No.

A78669

CAS No.

2835538-69-5

AChE-IN-25

AChE-IN-25 is a potent and selective uncompetitive inhibitor of acetylcholinesterase (AChE), exhibiting an IC50 value of 2.95 µM. This compound demonstrates significant potential for modulating cholinergic activity, making it a valuable tool in Alzheimer's disease research and related neurodegenerative studies. Its ability to effectively inhibit AChE can aid in understanding and investigating therapeutic strategies targeting cholinergic deficiencies.

Cat. No.

A78670

CAS No.

2978753-64-7

AChE-IN-37

AChE-IN-37 is an acetylcholinesterase inhibitor featuring an IC50 value of 0.23 μM. This compound modulates reactive oxygen species (ROS) levels and influences the gene expression of NRF2. AChE-IN-37 is applicable in research focused on neurodegenerative diseases and oxidative stress-related studies.

Cat. No.

A78671

CAS No.

1050587-57-9

Z164597606

Z164597606 is a selective butyrylcholinesterase (BChE) inhibitor, demonstrating IC50 values of 1.3 μM and 1.7 μM for equine and human BChE, respectively. The compound interacts with the enzyme through π-π stacking with the Trp82 residue, facilitating its inhibitory effect. Z164597606 is applicable in research focused on Alzheimer’s disease, enabling investigations into therapeutic strategies targeting cholinesterase activity.

Cat. No.

A78672

CAS No.

857-62-5

Anisopirol

Synonyms: R-2159

Anisopirol (R-2159) functions as an inhibitor of cholinesterase (ChE), which is crucial for neurotransmitter regulation. Research indicates that it may exhibit neuroprotective effects and could modulate various protein targets implicated in Alzheimer's disease. This compound is primarily utilized in studies focused on understanding the biochemical pathways involved in neurodegeneration and potential therapeutic strategies for Alzheimer's disease.

Cat. No.

A78673

CAS No.

1171708-92-1

AChE-IN-91

AChE-IN-91 is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 0.05 μM. It exhibits significant anticholinesterase activity, making it a valuable tool for research into neurological disorders, particularly Alzheimer's disease. This compound facilitates the study of cholinergic signaling and potential therapeutic strategies in neurodegeneration.

Cat. No.

A78674

CAS No.

25405-80-5

Isocorydine N-oxide

Synonyms: (+)-Isocorydine N-oxide

Isocorydine N-oxide is an alkaloid that functions as an acetylcholinesterase (AChE) inhibitor. This compound exhibits significant activity that may contribute to the modulation of neurotransmitter levels, making it a valuable tool in research focused on neurodegenerative diseases such as Alzheimer's disease. It is utilized to explore therapeutic strategies aimed at enhancing cholinergic function and improving cognitive outcomes in affected individuals.